MediPal Holdings マネジメント

マネジメント基準チェック /24

MediPal Holdingsの CEO はShuichi Watanabeで、 Apr2012年に任命され、の在任期間は 12.58年です。は、会社の株式の0.084%を直接所有しており、その価値は¥ 429.60M 。経営陣と取締役会の平均在任期間はそれぞれ9.9年と6.9年です。

主要情報

Shuichi Watanabe

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	12.6yrs
CEOの所有権	0.08%
経営陣の平均在職期間	9.9yrs
取締役会の平均在任期間	6.9yrs

経営陣の近況

Recent updates

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 05

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

Jun 25

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

May 22

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

May 08

CEO（最高経営責任者

Shuichi Watanabe (72 yo)

12.6yrs

在職期間

Mr. Shuichi Watanabe has been Chief Compliance Officer of MediPal Holdings Corporation since June 25, 2020. Mr. Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Shuichi Watanabe	Chief Compliance Officer	12.6yrs	データなし	0.084% ¥ 429.6m
Yuji Sakon	MD, GM of Administration Division & Director	11.4yrs	データなし	0.011% ¥ 56.5m
Toshihide Yoda	Senior MD of Investor Relations	1.4yrs	データなし	0.0063% ¥ 31.9m
Yasuhiro Choufuku	Executive VP & Director	8.4yrs	データなし	0.025% ¥ 127.7m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	no data	データなし	0.017% ¥ 88.4m

9.9yrs

平均在職期間

70yo

平均年齢

経験豊富な経営陣: 7459の経営陣は経験豊富で経験豊富です（平均在職期間は9.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Shuichi Watanabe	Chief Compliance Officer	24.8yrs	データなし	0.084% ¥ 429.6m
Yuji Sakon	MD, GM of Administration Division & Director	12.4yrs	データなし	0.011% ¥ 56.5m
Toshihide Yoda	Senior MD of Investor Relations	14.4yrs	データなし	0.0063% ¥ 31.9m
Yasuhiro Choufuku	Executive VP & Director	5.4yrs	データなし	0.025% ¥ 127.7m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	11.4yrs	データなし	0.017% ¥ 88.4m
Kuniko Shoji	Independent Outside Director	6.4yrs	データなし	データなし
Toshio Asano	Independent Outside Director	7.4yrs	データなし	0.0034% ¥ 17.2m
Hiroshi Iwamoto	Independent Outside Director	3.4yrs	データなし	データなし
Koichi Mimura	Director	4.4yrs	データなし	0.00096% ¥ 4.9m
Mitsuko Kagami	Independent Outside Director	10.4yrs	データなし	データなし
Takuya Yoshida	Director	1.4yrs	データなし	0.00048% ¥ 2.5m
Imagawa Kuniaki	Director	2.4yrs	データなし	データなし

6.9yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: 7459の取締役会は経験豊富であると考えられます ( 6.9年の平均在任期間)。

MediPal Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Consensus EPS estimates increase by 11%

New major risk - Revenue and earnings growth

Second quarter 2025 earnings released: EPS: JP¥61.05 (vs JP¥28.08 in 2Q 2024)

Returns On Capital At MediPal Holdings (TSE:7459) Have Stalled

Upcoming dividend of JP¥30.00 per share

MediPal Holdings (TSE:7459) Will Pay A Dividend Of ¥30.00

MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024

Calculating The Fair Value Of MediPal Holdings Corporation (TSE:7459)

MediPal Holdings (TSE:7459) Has Announced A Dividend Of ¥30.00

Dividend of JP¥30.00 announced

Now 27% undervalued after recent price drop

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2025 earnings released: EPS: JP¥42.95 (vs JP¥52.32 in 1Q 2024)

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024

MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

Full year 2024 earnings: EPS exceeds analyst expectations

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Price target increased by 9.5% to JP¥2,475

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

Price target increased by 12% to JP¥2,198

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 14%

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Now 22% undervalued

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 20% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue and earnings beat expectations

New 90-day high: JP¥2,141

Analysts update estimates

Analysts update estimates

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020

マネジメント基準チェック /24